aTYR PHARMA (ATYR) Net Margin (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly Net Margin came in at 15115.79% in Q3 2025, down 55.18% on a QoQ basis from 9740.85% in Q1 2024.

aTYR PHARMA (ATYR) Net Margin (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has 6 years of Net Margin data on file, last reported at 15115.79% in Q3 2025.

Quarterly Net Margin changed N/A year-over-year to 15115.79% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 41738.42% (changed N/A YoY) and the FY2025 annual result came in at 115698.42%, down 3394778.0% from the prior year.
Net Margin eased to 15115.79% in Q3 2025, from 9740.85% in the prior quarter.
In the past five years, Net Margin ranged from a high of 77.07% in Q4 2022 to a low of 15115.79% in Q3 2025.
A 4-year average of 7585.06% and a median of 7573.68% in 2023 frame the typical range for Net Margin.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	30.23%
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	31.16%
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	12.74%
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	-16.51%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	12.09%
10	aTYR PHARMA	50.30 Mn	-7.12 Mn	-	-

Download Data